NHS Midlands Bets on AI Scribe Heidi in Largest Ever Ambient Voice Procurement

The Deal

NHS England Midlands has named Heidi Health as its sole supplier on a new regional procurement framework for AI-powered ambient voice technology (AVT), covering 15 acute and community trusts, all Midlands integrated care boards, and 1,239 GP practices. The deal reaches 70,000 clinicians, the largest procurement of its kind ever undertaken in the NHS.

Deployment is already under way. Dudley Group NHS Foundation Trust, Walsall Healthcare NHS, and The Royal Wolverhampton NHS Trust went live in May 2026, with Sandwell and West Birmingham Hospitals following shortly after.

The tool records consultations and uses generative AI to convert speech into structured medical documentation: notes, letters, discharge summaries. Clinicians review each output before uploading to patient records. Heidi operates across 110 languages, a feature that trusts say is breaking down barriers for patients whose first language is not English.

Numbers That Matter

The headline outcomes from early Midlands trials are striking. A same-day emergency care unit cut documentation time by 80%. A rheumatology service cleared a six-month patient-letter backlog in 14 days. Dr Mohammed Jamil Aslam, an emergency consultant at Walsall Manor Hospital, reports saving six minutes per consultation, time that goes straight back to patients.

A major NHS England-sponsored study underpins the regional case: AI scribes produced a 23.5% increase in direct patient interaction time per appointment alongside an 8.2% reduction in appointment length overall.

Those numbers arrive in favourable national company. A broader NHS England announcement on 4 July committed the health service to rolling out AI notetaking tools nationally, prioritising day-case hospital appointments where ambient scribing has already demonstrated measurable admin reductions. The national plan sits inside a £10 billion technology transformation programme projected to generate £41 billion in total benefits over the next decade.

Why the Midlands Went First

Ravinder Kaur Sahota, group chief information officer at Dudley Group and Sandwell and West Birmingham Trust, said the trust "built the clinical safety case, the business case, and the evidence base so that other trusts would not have to start from scratch." That groundwork matters: the procurement framework gives any GP practice or trust in the Midlands a pre-cleared route to deploy AVT without a separate local procurement, drastically compressing the usual NHS buying cycle.

Heidi is one of 23 suppliers listed on NHS England's self-certified AVT registry, which launched in January 2026. Winning a sole-supplier framework position at this scale, ahead of better-resourced EMR incumbents, is commercially significant. Some independent health technology analysts have questioned whether the sole-supplier model appropriately preserves optionality as the market matures, a debate worth watching as other regions consider their own frameworks.

The Regulatory Backdrop

Ambient voice tools that generate clinical documentation sit in a regulatory grey zone. The MHRA's draft Medical Devices (Amendment) Regulations 2026, published on 11 May 2026, formalise Predetermined Change Control Plans (PCCPs) for AI-enabled software, allowing manufacturers to define anticipated model updates in advance without repeated conformity assessments. Those rules are expected to be laid in Parliament in Q4 2026, entering into force around Spring 2027.

For ambient scribing products, the timing matters. Software that supports clinical decisions or generates documentation that directly influences clinical action could, in certain configurations, cross the threshold into regulated AI as a Medical Device territory. Until the MHRA's forthcoming dedicated AI framework, expected later this year and informed by the National AI Commission's findings, vendors and NHS buyers face genuine regulatory ambiguity.

What the Market Data Says

That ambiguity appears to be dampening enthusiasm at the company-formation level, at least on paper. AI Business Dispatch analysis of Companies House and IPO data (as of July 2026) recorded just 57 new SIC 86.10 (hospital activities) incorporations in 2026-Q3, a fall of 81.7% against the prior period, while UK Class 10 trademark filings (covering medical instruments and devices) dropped to 289 in the same quarter, down 76.9%. Perhaps most telling: 99.4% of active SIC 86.10 companies hold no Class 10 trademark, suggesting the overwhelming majority of new health-tech entrants are either not building regulated device products or are deferring brand protection until late in the regulatory journey.

The Heidi deal represents the opposite of that wait-and-see posture: a product already in clinical use, backed by hard outcome data, scaled through a procurement mechanism designed to short-circuit institutional inertia.

Scale introduces its own risks, however. Healthwatch England polling published last week found the public split on AI scribes, with most respondents wanting explicit consent before any tool listens in on a consultation. Patient consent frameworks, data governance, and post-market clinical monitoring will determine whether the Midlands procurement becomes a template or a cautionary tale.